Literature DB >> 9041466

A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons.

P S Subramaniam1, H M Johnson.   

Abstract

Type I interferons (IFN), such as IFN-alpha, are potent antiproliferative and antitumor agents. IFN-tau, originally identified as a pregnancy recognition hormone, is a type I IFN that is related to IFN-alpha. We examine here the mechanism of the antiproliferative effects of IFN-alpha and IFN-tau in terms of their effects on intracellular events that regulate the cell cycle. Both IFN inhibited proliferation of the human Burkitt lymphoma cell line, Daudi, causing accumulation of cells in the G1 phase of the cell cycle. IFN-alpha was more effective than IFN-tau in this regard. Both IFN were found to inhibit the kinase activity of the cyclin-dependent kinase cdk2 in a manner that correlated with their relative abilities to cause cells to accumulate in the G1 phase of the cell cycle. Further, IFN treatment did not affect the expression of cdk2 protein, suggesting that the IFN modulated cdk2 activity through a cdk inhibitor. Consistent with this conclusion, both IFN induced the expression of the cyclin-dependent kinase inhibitor protein p21. The levels of p21 induced also correlated with the relative abilities of the IFN to inhibit cdk2 activity and to arrest cell growth in the G1 phase of the cell cycle. Moreover, following IFN treatment, increased levels of p21 were found complexed with cdk2, consistent with its role in the inhibition of cdk2 activity. These data suggest that p21-mediated inhibition of cdk2 activity plays an important role in the antiproliferative activity of type I IFN. The findings highlight interesting similarities between these cytokines and the products of tumor suppressor genes, such as p53, and may indicate a mechanism for the antitumor effects of the type I IFN.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041466     DOI: 10.1089/jir.1997.17.11

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

1.  Inhibition of the glioblastoma cell cycle by type I IFNs occurs at both the G1 and S phases and correlates with the upregulation of p21(WAF1/CIP1).

Authors:  T Tanabe; S L Kominsky; P S Subramaniam; H M Johnson; B A Torres
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

2.  Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis.

Authors:  K M Detjen; K Farwig; M Welzel; B Wiedenmann; S Rosewicz
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

3.  ROS mediates interferon gamma induced phosphorylation of Src, through the Raf/ERK pathway, in MCF-7 human breast cancer cell line.

Authors:  Kazem Zibara; Asad Zeidan; Hassan Bjeije; Nouhad Kassem; Bassam Badran; Nabil El-Zein
Journal:  J Cell Commun Signal       Date:  2016-11-12       Impact factor: 5.782

4.  Osteopontin regulates ubiquitin-dependent degradation of Stat1 in murine mammary epithelial tumor cells.

Authors:  Chengjiang Gao; Zhiyong Mi; Hongtao Guo; Paul C Kuo
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

5.  Regulation of p21/CIP1/WAF-1 mediated cell-cycle arrest by RNase L and tristetraprolin, and involvement of AU-rich elements.

Authors:  Latifa Al-Haj; Perry J Blackshear; Khalid S A Khabar
Journal:  Nucleic Acids Res       Date:  2012-06-19       Impact factor: 16.971

Review 6.  From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer.

Authors:  Carolina S Ilkow; Stephanie L Swift; John C Bell; Jean-Simon Diallo
Journal:  PLoS Pathog       Date:  2014-01-16       Impact factor: 6.823

7.  Traumatic Brain Injury Induces cGAS Activation and Type I Interferon Signaling in Aged Mice.

Authors:  James P Barrett; Susan M Knoblach; Surajit Bhattacharya; Heather Gordish-Dressman; Bogdan A Stoica; David J Loane
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.